Shopping Cart
Remove All
Your shopping cart is currently empty
Zenocutuzumab
😃Good
Catalog No. T76948Cas No. 1969309-56-5
Alias R040517, R 040517, PB4188, PB 4188, MCLA-128, MCLA128
Zenocutuzumab (MCLA-128) is a humanized antibody targeting the extracellular domains of HER2 and HER3. It can be used for research on tumors driven by NRG1 gene rearrangement.
Zenocutuzumab
Zenocutuzumab
😃Good
Purity: 97%
Catalog No. T76948Alias R040517, R 040517, PB4188, PB 4188, MCLA-128, MCLA128Cas No. 1969309-56-5
Zenocutuzumab (MCLA-128) is a humanized antibody targeting the extracellular domains of HER2 and HER3. It can be used for research on tumors driven by NRG1 gene rearrangement.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $396 | In Stock | In Stock | |
| 5 mg | $1,190 | - | In Stock | |
| 10 mg | $1,880 | - | In Stock | |
| 25 mg | $2,830 | Inquiry | Inquiry |
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Batch Information
Select Batch
Purity:97%
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Zenocutuzumab (MCLA-128) is a humanized antibody targeting the extracellular domains of HER2 and HER3. It can be used for research on tumors driven by NRG1 gene rearrangement. |
| In vitro | Zenocutuzumab (MCLA-128) (0.001-1000 nM, treated for 96 hours) inhibits the growth of lung and breast cancer cell lines. [1] Zenocutuzumab (0.1-1000 nM, treated for 24 hours) induces apoptosis and triggers expression of markers of cell cycle arrest in lung and breast cancer cell lines by inhibiting phosphorylation of HER3 and AKT. [1] |
| In vivo | Zenocutuzumab (2.5-25 mg/kg, intraperitoneal injection once weekly for 28 days) significantly reduced tumor growth and triggered tumor shrinkage and even regression. [1] |
| Synonyms | R040517, R 040517, PB4188, PB 4188, MCLA-128, MCLA128 |
| Reactivity | Human |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Endotoxin | ＜ 1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | ERBB2/HER2/CD340 |
| Molecular Weight | 145.76 kDa |
| Cas No. | 1969309-56-5 |
| Color | Transparent |
| Appearance | Liquid |
| Isotype | Human IgG1 kappa |
| Recommended Isotype Control |
| Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy Zenocutuzumab | purchase Zenocutuzumab | Zenocutuzumab cost | order Zenocutuzumab | Zenocutuzumab in vivo | Zenocutuzumab in vitro | Zenocutuzumab molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.